Shares of Scholar Rock (SRRK) skyrocketed 362% on Monday after the company announced positive top-line results from the late-stage study, evaluating the efficacy and safety of its investigational muscle-targeted therapy, apitegromab, to treat spinal muscular atrophy (SMA). Apitegromab is a fully human monoclonal antibody inhibiting myostatin activation. Myostatin is a protein that is primarily produced in skeletal muscle cells and acts as a negative regulator of muscle growth. SMA is a genetic disorder that ...